奥氮平和利培酮治疗精神分裂症合并慢性乙肝患者的疗效分析及其对糖脂代谢的影响

发布时间：2018-06-03 18:10

本文选题：精神分裂症 + 慢性乙型病毒性肝炎　；参考：《中国新药杂志》2017年01期

【摘要】：目的:比较奥氮平和利培酮治疗精神分裂症合并慢性乙型病毒性肝炎(慢性乙肝)患者的疗效及其对糖脂代谢的影响。方法:将合并慢性乙肝的65例精神分裂症患者分为奥氮平组(n=32)和利培酮组(n=33),治疗8周。在治疗前及治疗后8周末采用阳性与阴性症状量表(PANSS)进行评分,评定疗效;比较2组治疗前后血糖、血脂变化和体质量改变。结果:奥氮平组和利培酮组治疗8周后PANSS减分率分别为65.6%和66.7%,差异无统计学意义(P0.05)。奥氮平组患者治疗后体质量指数(BMI)、空腹血糖、甘油三酯、总胆固醇和低密度脂蛋白升高。利培酮组患者治疗后空腹血糖、总胆固醇升高,但幅度低于奥氮平组。结论:利培酮治疗合并慢性乙肝的精神分裂症患者的疗效与奥氮平相当,但对糖脂代谢和BMI影响较小,较适于合并慢性乙肝精神分裂症患者的治疗。
[Abstract]:Aim: to compare the efficacy of olanzapine and risperidone in the treatment of schizophrenia with chronic hepatitis B (CHB) and its effect on glucose and lipid metabolism. Methods: 65 schizophrenic patients with chronic hepatitis B were divided into olanzapine group (n = 32) and risperidone group (n = 33) for 8 weeks. Positive and negative symptom scale (PANSS) was used to evaluate the efficacy before and after treatment, and the changes of blood glucose, blood lipid and body mass were compared before and after treatment. Results: the PANSS reduction rates of olanzapine group and risperidone group were 65.6% and 66.7% respectively after 8 weeks of treatment with no significant difference (P 0.05). In the olanzapine group, body mass index (BMI), fasting blood glucose, triglyceride, total cholesterol and low density lipoprotein increased after treatment. The fasting blood glucose and total cholesterol in risperidone group were higher than those in olanzapine group. Conclusion: the efficacy of risperidone in the treatment of schizophrenia with chronic hepatitis B is similar to that of olanzapine, but has little effect on glucose and lipid metabolism and BMI, so it is more suitable for the treatment of patients with chronic hepatitis B schizophrenia.
【作者单位】：北京回龙观医院心身医学科;
【基金】：北京市自然科学基金青年项目(7154208)
【分类号】：R749.3;R512.62

【相似文献】